184 related articles for article (PubMed ID: 8750190)
1. Gene therapeutic approach to primary and metastatic brain tumors: I. CD44 variant pre-RNA alternative splicing as a CEPT control element.
Asman DC; Dirks JF; Ge L; Resnick NM; Salvucci LA; Gau JT; Becich MJ; Cooper DL; Dougherty GJ
J Neurooncol; 1995 Dec; 26(3):243-50. PubMed ID: 8750190
[TBL] [Abstract][Full Text] [Related]
2. Differential expressions of CD44 variants in tumors affecting the central nervous system.
Resnick DK; Resnick NM; Welch WC; Cooper DL
Mol Diagn; 1999 Sep; 4(3):219-32. PubMed ID: 10553022
[TBL] [Abstract][Full Text] [Related]
3. Alternative splicing of CD44 pre-mRNA in human colorectal tumors.
Finn L; Dougherty G; Finley G; Meisler A; Becich M; Cooper DL
Biochem Biophys Res Commun; 1994 Apr; 200(2):1015-22. PubMed ID: 7513991
[TBL] [Abstract][Full Text] [Related]
4. Multisite and bidirectional exonic splicing enhancer in CD44 alternative exon v3.
Vela E; Hilari JM; Roca X; Muñoz-Mármol AM; Ariza A; Isamat M
RNA; 2007 Dec; 13(12):2312-23. PubMed ID: 17940137
[TBL] [Abstract][Full Text] [Related]
5. Chondroitin sulphate composition and structure in alternatively spliced CD44 fusion proteins.
Piepkorn M; Hovingh P; Bennett KL; Aruffo A; Linker A
Biochem J; 1997 Oct; 327 ( Pt 2)(Pt 2):499-506. PubMed ID: 9359422
[TBL] [Abstract][Full Text] [Related]
6. A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase.
Austin EA; Huber BE
Mol Pharmacol; 1993 Mar; 43(3):380-7. PubMed ID: 8450832
[TBL] [Abstract][Full Text] [Related]
7. Influence of intron length on alternative splicing of CD44.
Bell MV; Cowper AE; Lefranc MP; Bell JI; Screaton GR
Mol Cell Biol; 1998 Oct; 18(10):5930-41. PubMed ID: 9742110
[TBL] [Abstract][Full Text] [Related]
8. CD44 isoform expression in periodontal tissues: cell-type specific regulation of alternative splicing.
Hirano F; Hirano H; Hino E; Takayama S; Saito K; Kusumoto Y; Shimabukuro Y; Murakami S; Okada H
J Periodontal Res; 1997 Nov; 32(8):634-45. PubMed ID: 9409458
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD44 splice variants in human primary brain tumors.
Kaaijk P; Troost D; Morsink F; Keehnen RM; Leenstra S; Bosch DA; Pals ST
J Neurooncol; 1995 Dec; 26(3):185-90. PubMed ID: 8750184
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms regulating the tumor-targeting potential of splice-activated gene expression.
Hayes GM; Dougherty ST; Davis PD; Dougherty GJ
Cancer Gene Ther; 2004 Dec; 11(12):797-807. PubMed ID: 15359288
[TBL] [Abstract][Full Text] [Related]
11. SR proteins regulate V6 exon splicing of CD44 pre-mRNA.
Loh TJ; Moon H; Jang HN; Liu Y; Choi N; Shen S; Williams DR; Jung DW; Zheng X; Shen H
BMB Rep; 2016 Nov; 49(11):612-616. PubMed ID: 27530682
[TBL] [Abstract][Full Text] [Related]
12. A new alternatively spliced exon between v9 and v10 provides a molecular basis for synthesis of soluble CD44.
Yu Q; Toole BP
J Biol Chem; 1996 Aug; 271(34):20603-7. PubMed ID: 8702806
[TBL] [Abstract][Full Text] [Related]
13. CD44 expression patterns in breast and colon tumors: a PCR-based study of splice variants.
Rodriguez C; Monges G; Rouanet P; Dutrillaux B; Lefrançois D; Theillet C
Int J Cancer; 1995 Oct; 64(5):347-54. PubMed ID: 7591309
[TBL] [Abstract][Full Text] [Related]
14. SC35 promotes splicing of the C5-V6-C6 isoform of CD44 pre-mRNA.
Loh TJ; Moon H; Cho S; Jung DW; Hong SE; Kim DH; Green MR; Zheng X; Zhou J; Shen H
Oncol Rep; 2014 Jan; 31(1):273-9. PubMed ID: 24173428
[TBL] [Abstract][Full Text] [Related]
15. Trans-acting factors regulate the expression of CD44 splice variants.
Konig H; Moll J; Ponta H; Herrlich P
EMBO J; 1996 Aug; 15(15):4030-9. PubMed ID: 8670907
[TBL] [Abstract][Full Text] [Related]
16. The p53-induced RNA-binding protein ZMAT3 is a splicing regulator that inhibits the splicing of oncogenic CD44 variants in colorectal carcinoma.
Muys BR; Anastasakis DG; Claypool D; Pongor L; Li XL; Grammatikakis I; Liu M; Wang X; Prasanth KV; Aladjem MI; Lal A; Hafner M
Genes Dev; 2021 Jan; 35(1-2):102-116. PubMed ID: 33334821
[TBL] [Abstract][Full Text] [Related]
17. Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon.
Jackson DG; Bell JI; Dickinson R; Timans J; Shields J; Whittle N
J Cell Biol; 1995 Feb; 128(4):673-85. PubMed ID: 7532175
[TBL] [Abstract][Full Text] [Related]
18. CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor.
Bennett KL; Jackson DG; Simon JC; Tanczos E; Peach R; Modrell B; Stamenkovic I; Plowman G; Aruffo A
J Cell Biol; 1995 Feb; 128(4):687-98. PubMed ID: 7532176
[TBL] [Abstract][Full Text] [Related]
19. Arrayed primer extension computing with variant mRNA splice forms. Multiple isoforms of CD44 in a human breast tumor.
Kim H; Pirrung MC
J Am Chem Soc; 2002 May; 124(18):4934-5. PubMed ID: 11982338
[TBL] [Abstract][Full Text] [Related]
20. Multiple intron retention occurs in tumor cell CD44 mRNA processing.
Goodison S; Yoshida K; Churchman M; Tarin D
Am J Pathol; 1998 Oct; 153(4):1221-8. PubMed ID: 9777953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
